NURA USA announces exclusive US partnership with Molecules BioLabs for BerbiQ

The partnership reinforces NURA’s commitment to delivering innovative, science-backed ingredients
that address key health categories, including metabolic health

NURA USA, a leading ingredient solutions provider for the food, beverage, and supplement
industries, announced its exclusive US distribution partnership with Molecules BioLabs for BerbiQ,
a next-generation, highly bioavailable berberine ingredient. 

The partnership reinforces NURA’s commitment to delivering innovative, science-backed ingredients
that address key health categories, including metabolic health. 

“We are proud to partner with Molecules BioLabs to bring BerbiQ to the US market and address
long-standing challenges in berberine efficacy,” said Lily Ruan, President of NURA USA.
 
BerbiQ represents a breakthrough in berberine delivery, utilizing proprietary OMICS Technology and
advanced bio-nanotechnology to significantly enhance absorption and efficacy. By complexing
berberine with synergistic components such as silymarin and coconut milk proteins, BerbiQ enables
brands to deliver metabolic health support in optimised formats. 

Backed by published research demonstrating 4.26× higher bioavailability compared to standard
berberine (ACS Omega, 2025), the company highlighted BerbiQ’s sustained-release formulation
designed to provide prolonged systemic support. The ingredient features a clean-label profile, is
vegan and ethically sourced, and offers strong versatility for use across a wide range of applications,
including capsules, gummies, and functional foods.

“Choosing the right partner for the U.S. market was critical for us. NURA USA’s commitment to
transparency, quality, and deep technical expertise makes them the ideal bridge for our research.
We are confident that NURA will provide the high-level support and distribution excellence that an
advanced ingredient like BerbiQ deserves,” said Dr Sreeraj Gopi, Founder and MD, Molecules BioLabs.